A Five Years Budget Impact Analysis of The Introduction of Adalimumab For Crohn's Disease Patients From The Perspective of The Brazilian Private Health Care System.

Inflammatory bowel diseases (IBD), most studied types are Ulcerative colitis (UC) and Crohn’s disease (CD), are related to an immunological imbalance of the intestinal mucosa, mainly associated with cells of the adaptive immune system, which respond against self-antigens producing chronic inflammatory conditions in these patients1. As CD is a prevalent and very expensive medical condition, its economic burden on Western countries’ healthcare systems and societies is large2. INTRODUCTION OBJECTIVE CONCLUSION